Bristol Myers scraps $100M Orum-partnered cancer drug

Bristol Myers Squibb has ended development of a twist on the popular antibody-drug conjugate field. The Phase 1 asset that was axed is BMS-986497/ORM-6151, according to a Thursday regulatory filing from ...